Select region:

Clinical trials located in

Toulouse

Toulouse city is located in France. Currently, 20 clinical trials are being conducted in this city.

Toulouse, known as “La Ville Rose” due to its distinctive terracotta brick architecture, is a vibrant city in southern France. It is the fourth-largest city in the country and serves as the capital of the Occitanie region. Toulouse is renowned for its rich history, dating back to the Roman era, and its significant role in the aerospace industry, housing the headquarters of Airbus. The city boasts a unique blend of ancient and modern, with its historic center, bustling markets, and cutting-edge space exploration facilities. Toulouse also enjoys a lively cultural scene, with numerous festivals, theaters, and museums, including the Foundation Bemberg and the Toulouse Space Center.

  • CT-EU-00083874

    Study to find the best way to administer pegaspargase in children with acute lymphoblastic leukemia

    This is a study to investigate treatment strategies for children and adolescents diagnosed with acute lymphoblastic leukemia (ALL). The study focuses on evaluating the efficacy of a drug called pegaspargase. The drug works by depriving tumor cells of essential nutrients, contributing to its potential efficacy against ALL in pediatric patients. The study aims to determine the optimal way to administer pegaspargase, comparing a single high dose with two lower doses, with additional doses later in treatment. For those at highest risk, a more intensive treatment plan is being investigated. This includes two larger initial doses, followed by additional doses later in treatment. The study is evaluating factors such as potential serious side effects and overall treatment efficacy.

  • CT-EU-00091440

    Investigating new drug, JNJ-75276617 for the treatment of patients with acute leukemia

    This study is about a new medicine called JNJ-75276617, designed to help patients with a type of blood cancer called Acute Leukemia. Acute leukemia is an illness where the bone marrow makes too many white blood cells that are abnormal. This study is divided into two parts: first, to figure out the best dose of the new medicine, and second, to check if it’s safe at that dose. For up to 2 years and 10 months, researchers will follow participants closely and check for any changes in their health. They will look at the number of participants who experience bad side effects, how much of the drug is in their bodies, and how the disease is responding to the new medicine. The main goal is to find a dose of the drug that’s both safe and can possibly help patients with acute leukemia.

  • CT-EU-00084629

    Testing the safety and impact of a new potential drug on leukemia and lymphoma patients

    This study is designed to assess the effectiveness of a new medication, DR-01, in individuals diagnosed with Large Granular Lymphocytic Leukemia or certain forms of Lymphomas, specific types of blood cancer. DR-01 is being tested for the first time in humans across multiple centers or hospitals. The study consists of two main phases. In Phase 1, meticulous attention is devoted to scrutinizing the safety profile of DR-01 and gauging its tolerability by individuals. In Phase 2, the study examines the medication’s efficacy in combating the targeted cancer. This multifaceted approach underscores a comprehensive endeavor to unveil not only the safety but also the therapeutic potential of DR-01 in the realm of blood cancer treatment.

  • CT-EU-00091315

    Testing infigratinib in children aged 3 to 11 years with achondroplasia

    This study focuses on evaluating the medication Infigratinib in young children aged 3 to 11 diagnosed with Achondroplasia who previously participated in the PROPEL study for at least 6 months. The primary objectives of this study are to assess the safety profile of Infigratinib in this specific age group, evaluate the children’s tolerance to potential side effects, and investigate the therapeutic efficacy of the medication for treating Achondroplasia. During the study, doses of Infigratinib will be incrementally increased to determine the optimal and most effective dosage for the participants.

  • Continued Parsaclisib treatment for B-cell cancer patients

    This is a phase II clinical trial focused on providing continuation of treatment with a drug called parsaclisib to people diagnosed with B-cell malignancies. The main goal of this study is to expand the treatment regimen established in the previous study. Study participants will receive parsaclisib as a stand-alone therapy (monotherapy) or in combination with other therapeutic agents, which may include itacitinib, ruxolitinib or ibrutinib. The study aims to facilitate participants’ ongoing care and contribute to the broader field of medical research by collecting data on the effectiveness and safety of prolonged use of parsaclisib.

    AustriaBelgiumCzechiaDenmarkFranceHungaryItalyNorwayPolandSpainSwedenUnited Kingdom
  • Testing a new combination therapy with acalabrutinib for a specific type of lymphoma

    This clinical trial is investigating a new combination therapy for diffuse large B-cell lymphoma, a type of lymphoma. The treatment combines Acalabrutinib, a targeted therapy drug, with R-CHOP, a chemotherapy mix consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, a standard chemotherapy regimen. The aim of the study is to evaluate the safety and effectiveness of this combination in improving patient outcomes. It focuses on patients who have not been previously treated for lymphoma. The study aims to find better treatment strategies for this particular type of lymphoma.

    AustriaBelgiumCzechiaFranceGermanyItalyPolandPortugalSpain
  • Testing a new inhaled drug for pulmonary arterial hypertension

    This study focuses on the efficiency and safety of a new inhaled drug – MK-5475 – for patients suffering from Pulmonary Arterial Hypertension (PAH). The study is divided into two parts: phase 2 and phase 3. In phase 2, the researchers will compare three different doses of MK-5475 with a placebo over a base period of 12 weeks. The goal is to find out if any of the doses can decrease the patient’s pulmonary vascular resistance (PVR), which is the resistance that the heart must overcome to pump blood through the lungs. In Phase 3 of the study, the best performing dose from Phase 2 will be used to confirm its long-term effectiveness, safety, and tolerability over a 12-week base period with a follow-up period of up to five years. The focus is to see if this dose is better than a placebo in improving the patient’s walking distance over 6 minutes. The study aims at improving the quality of life and physical health of PAH patients with the help of the new drug.

    BelgiumFranceGermanyItalyPolandSwedenUnited Kingdom
  • Venetoclax in recurrence of blood cancer after previous stem cell transplantation

    This study aims to investigate the effectiveness and safety of a novel treatment approach, combining the drugs venetoclax and azacitidine, along with donor lymphocyte infusion (DLI) in patients experiencing a relapse of one of two of blood-related disorders: myelodysplastic syndrome (condition where blood cells do not develop properly) or acute myeloid leukemia (bone marrow cells become abnormal and begin to accumulate in excess), following stem cell transplantation. The study involves a group of patients for whom standard treatments have not yielded satisfactory results. The objective is to understand whether the combination of new drugs and donor lymphocyte infusion can effectively control these blood disorders, especially after stem cell transplantation. Researchers are monitoring side effects, assessing disease progression, and determining the safety of the procedure. The results may provide valuable insights into effective therapeutic strategies for these challenging blood-related disorders.
    France
  • Testing sotatercept with regular treatment in severe pulmonary arterial hypertension patients

    This investigation seeks to assess the effect of a new drug named Sotatercept on people who are suffering from a serious lung disease called ‘Pulmonary Arterial Hypertension’ (PAH). The trial is intended for individuals with high-risk PAH who are facing significant danger of death. The main goal is to find out if incorporating Sotatercept into the standard treatment can improve outcomes and potentially enhance the chances of survival. Participants who enroll will receive either Sotatercept in addition to their current medication or a placebo alongside their regular treatment.

    BelgiumFranceGermanyItalyNetherlandsSpainUnited Kingdom
  • Fianlimab and cemiplimab: a new treatment for melanoma patients

    The study is underway to determine the most effective treatments in preventing the recurrence of melanoma, a form of skin cancer, following surgical removal. The medicines being tested are Fianlimab and Cemiplimab together or another medicine called Pembrolizumab. The trial aims to assess whether the Fianlimab and Cemiplimab combination outperforms Pembrolizumab in preventing cancer recurrence and if patients administered Fianlimab and Cemiplimab live longer. Additionally, the study seeks insights into the impact of treatments on patients’ quality of life, the occurrence of minor or major side effects, and how these drugs behave inside the patient’s body.

    BelgiumCzechiaFranceGermanyGreeceItalyPolandRomaniaSpainUnited Kingdom
  • Comparing treatments for new Large B-cell lymphoma patients

    The trial aims to analyze and compare two drug treatments for people who have a large B-Cell Lymphoma, a kind of cancer that affects a certain type of white blood cells, and have not yet started their treatment. The first treatment is a combination of glofitamab, polatuzumab vedotin, and other common drugs used for this condition: rituximab, cyclophosphamide, doxorubicin, and prednisone. The second treatment is the same, but doesn’t include the glofitamab. The goal is to understand which treatment is more effective and safer for the patient.

    BelgiumDenmarkFranceGermanyItalyPolandSpainUnited Kingdom
  • Children’s study on sotatercept for pulmonary arterial hypertension

    This study evaluates the safety and tolerability of sotatercept in children aged 1 to 17 years with Pulmonary Arterial Hypertension (PAH). Over 24 weeks, 42 participants will receive sotatercept to understand how the body processes the drug and its effects. The study will monitor various health parameters, including blood pressure, heart function, and quality of life. Key outcomes include measuring serum concentrations of sotatercept, changes in heart and lung function, and overall well-being. This trial aims to improve treatment for children with PAH.

    FranceGermanyNetherlandsPolandSpainUnited Kingdom
  • Testing nivolumab alone and with Ipilimumab for advanced bowel cancer

    This study is about testing different treatments for a type of advanced bowel cancer called Metastatic Colorectal Cancer, which offers certain genetic features (called MSI-H or dMMR). The study aims to compare the efficacy of treatment approaches for cancer. One involves the use of the drug Nivolumab alone, and the other combines Nivolumab with another drug called Ipilimumab. These approaches will be compared against the benefits of conventional chemotherapy, as determined by the treating physician. The study will evaluate factors such as the extent of cancer shrinkage and the duration of growth inhibition.

    FranceGreeceItaly
  • Sotatercept treatment study for new Pulmonary Hypertension patients

    This study is an important test where doctors are looking at how a drug called Sotatercept can help people struggling with Pulmonary Arterial Hypertension (or PAH for short). The goal is to see whether this drug can delay or prevent the condition from getting worse. PAH makes it really hard for patients to breathe because it affects lungs and heart. The testing process is being done in a fair and careful way. Half of the patients will get the drug, and the others will get a ‘placebo’ which doesnt contain any medicine. The doctors will look at the effect on patients over time. The study is looking specifically at patients who were recently diagnosed with PAH and are at risk for the disease to get worse.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Testing golcadomide for safety & effectiveness in non-Hodgkin lymphomas

    This trial is about testing the safety and effectiveness of a drug called Golcadomide for people with a certain type of cancer called Non-Hodgkin Lymphomas that has come back or not responded to treatment. This drug can be taken by mouth and will be tested alone or together with other drugs used to treat lymphoma. It is for patients who tried at least two other treatments for their cancer, or if there arent suitable treatment for them. First, different doses of Golcadomide will be given to see which amount can be tolerated without causing too many side effects. Once that’s figured out, the trial will look at how well the chosen dose works either alone or with other lymphoma drugs. The researchersa will also study if eating food together with the drug will affect how the drug works and its safety.

    AustriaDenmarkFranceItalySpainUnited Kingdom
  • Understanding the effects of tominersen on early-stage Huntington’s Disease

    This clinical trial focuses on evaluating the investigational drug, tominersen, in people in the early stages of Huntington’s disease-a genetic disorder characterised by the progressive breakdown of nerve cells in the brain. This study aims to understand the potential of tominersen to slow the progression of the disease and improve quality of life by administering different doses or placebo directly into the spinal cord to target the areas of the brain most affected by the disease. Participants’ health status will be rigorously monitored and a series of assessments will be conducted to track changes in motor function, cognitive abilities and emotional wellbeing. Additionally, the study will measure specific biomarkers to assess the biological impact of treatment, offering valuable information for tailoring future therapies. This study represents an important opportunity to better understand Huntington’s disease and explore effective treatment options.

    AustriaDenmarkFranceGermanyItalyPolandPortugalSpainUnited Kingdom
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • A study on crovalimab in children with aHUS

    This study is about testing a medicine called Crovalimab in children who have a blood and kidney disease called Atypical Hemolytic Uremic Syndrome or aHUS for short. This trial is going to answer two key questions – is Crovalimab effective in treating aHUS and is it safe for kids to use without damaging side effects? The doctors will also be looking at how the child’s body handles the medicine, like how it gets absorbed, breaks down, and gets removed from their body. This helps figure out how often the medicine should be given for it to work best.

    BelgiumFranceHungaryItalyPolandSpain
  • Study of lacutamab in T-cell lymphoma

    This trial involves a medication called lacutamab, which will be given to patients who have a type of blood cancer known as peripheral T-cell lymphoma, and their disease has either come back after previous treatment or didn’t respond at all. Some patients in the study will receive lacutamab in combination with a common chemotherapy drugs gemcitabine and oxaliplatine, while others will get only gemcitabine and oxaliplatine. A key aim of this study is to find out if lacutamab is both safe and effective. The study is designed not to compare the two treatments directly, but to check our assumptions for deciding the number of people for the trial. The number of participants getting lacutamab is bigger.

    BelgiumFranceGermanySpain
  • Studying riliprubart’s effect on the prevention and treatment of antibody-mediated rejection

    The aim of this study is to test a new drug called Riliprubart (BIVV020) to see if it can help address a common problem in kidney transplant patients called antibody-mediated rejection (AMR). AMR happens when the body fights against the new kidney. The study consists of two parts: group one tests whether Riliprubart can prevent the development of antimicrobial resistance, while group B tests whether it can help if antimicrobial resistance already exists. The test also checks whether the drug is safe, how it works in the body and whether the body perceives it as something foreign. The study lasts about 2 years, during which doctors carefully monitor the condition of the patients’ kidneys, possible side effects and how the drug moves through the body after administration.

    FranceGermanyItalySpainSweden

See more clinical trials in other cities in France:

.